September 2025
1. NAIK V, Nekkalapudi A, Boopathy AV, Falkard B, et al
   Emergence of in vitro resistance to lenacapavir is similar across HIV-1 subtypes.
   AIDS. 2025 Sep 18. doi: 10.1097/QAD.0000000000004334.
   

   >> Share

   
   June 2025
2. MERAD Y, Mariaggi AA, Karmochkine M, Slama L, et al
   Virological success despite archived INSTI drug resistance mutations on INSTI-based antiretroviral regimens.
   AIDS. 2025 Jun 5. doi: 10.1097/QAD.0000000000004251.
   

   >> Share

   
   May 2025
3. CLEMENTE T, Bellomo M, Raccagni AR, Lolatto R, et al
   Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV.
   AIDS. 2025 May 3. doi: 10.1097/QAD.0000000000004225.
   

   >> Share

   
   April 2025
4. ZHANG R, Chung SL, Lee SS, Wong NS, et al
   Prevalence and resistance patterns of Mycoplasma genitalium infection in people living with HIV: a systematic review and meta-analysis.
   AIDS. 2025 Apr 22. doi: 10.1097/QAD.0000000000004219.
   

   >> Share

   
   
5. GLENN JS, Bennett A, Mackie N, Lyall H, et al
   The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.
   AIDS. 2025 Apr 4. doi: 10.1097/QAD.0000000000004202.
   

   >> Share

   
   March 2025
6. MUCCINI C, Spagnuolo V, Zazzi M, Castagna A, et al
   People with four-class drug-resistant HIV-1 may have low levels of intact DNA.
   AIDS. 2025;39:475-476.
   

   >> Share

   
   
7. INZAULE S, Jordan MR, Fokam J, Hamers RL, et al
   Non-canonical HIV drug resistance mutations: need to close existing gaps.
   AIDS. 2025 Mar 6. doi: 10.1097/QAD.0000000000004170.
   

   >> Share

   
   February 2025
8. WAGNER T, Levy I, Wieder-Finesod A, Wax M, et al
   Drug resistance testing at regimen failure in individuals diagnosed with HIV-1 between 2010 and 2018 in Israel.
   AIDS. 2025 Feb 3. doi: 10.1097/QAD.0000000000004138.
   

   >> Share

   
   October 2024
9. ENI-OLUTU A, Mackie NE, Glenn J, Bailey A, et al
   Emerging integrase resistance in an international perinatal virtual clinic.
   AIDS. 2024 Oct 28. doi: 10.1097/QAD.0000000000004048.
   

   >> Share

   
   
10. CLEMENTE T, Pontillo D, Malagnino V, Calza L, et al
    Cancer in people with multidrug-resistant HIV.
    AIDS. 2024;38:1801-1806.
    

    >> Share

    
    September 2024
11. ZANIEWSKI E, Skrivankova VW, Brazier E, Avihingsanon A, et al
    Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.
    AIDS. 2024 Sep 5. doi: 10.1097/QAD.0000000000004007.
    

    >> Share

    
    
12. BURGER D, Wttewaal E, Oosterhof P, Stalenhoef J, et al
    Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.
    AIDS. 2024;38:1728-1729.
    

    >> Share

    
    July 2024
13. KARABAY O
    Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
    AIDS. 2024;38:1273.
    

    >> Share

    
    March 2024
14. PAPAIOANNU BORJESSON R, Galli L, Lolatto R, Menzaghi B, et al
    Lower aids-related hospitalizations in women living with HIV multidrug resistance.
    AIDS. 2024;38:435-438.
    

    >> Share

    
    February 2024
15. GONCALVES P, Barreto J, Santos M, Leal S, et al
    HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde, 2019-2021.
    AIDS. 2024 Feb 13. doi: 10.1097/QAD.0000000000003866.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share